Author byline as per print journal: Tomás Abbot1, MSc; Nicolás Armijo1, MSc; Robin Piron2, PhD; Manuel Espinoza1, 3, PhD
Introduction: In Chile, access disparities and budget constraints affect the treatment of non-Hodgkin lymphoma patients, even though therapies like rituximab are covered by the Regime of Explicit Health Guarantees. Biosimilars like Rixathon® offer a compelling alternative with similar efficacy at lower cost. This study conducted a budget impact analysis to assess the introduction of Rixathon® for follicular lymphoma (FL) and diffuse large B-cell non-Hodgkin lymphoma (DLBCL) patients from Chilean healthcare system perspective. |
Submitted: 5 December 2023; Revised: 19 February 2024; Accepted: 26 February 2024; Published online first: 4 March 2024
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.
This manuscript has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.
Source URL: https://gabi-journal.net/budget-impact-analysis-of-a-rituximab-intravenous-biosimilar-in-patients-with-follicular-lymphoma-and-large-b-cell-non-hodgkin-lymphoma-in-chile.html
Copyright ©2024 GaBI Journal unless otherwise noted.